BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2017

Dec 22, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2017-12-20

Reporting Person: STAAB THOMAS R II (Senior Vice President and CFO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-20	Emp. Stock Option (Right to Buy)	$5.04	A	100000	Acquired	2027-12-20	Common Stock (100000)	Direct

Footnotes

F1: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.